[HTML][HTML] Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with …
Annals of oncology, 2012•Elsevier
Background Osteonecrosis of the jaw (ONJ) has been reported in patients receiving
bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes
were evaluated in a combined analysis of three phase III trials in patients with metastatic
bone disease receiving antiresorptive therapies. Patients and methods Patients with bone
metastases secondary to solid tumors or myeloma were randomly assigned to receive either
sc denosumab (120 mg) or iv zoledronic acid (4 mg) every 4 weeks. On-study oral …
bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes
were evaluated in a combined analysis of three phase III trials in patients with metastatic
bone disease receiving antiresorptive therapies. Patients and methods Patients with bone
metastases secondary to solid tumors or myeloma were randomly assigned to receive either
sc denosumab (120 mg) or iv zoledronic acid (4 mg) every 4 weeks. On-study oral …
Background
Osteonecrosis of the jaw (ONJ) has been reported in patients receiving bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes were evaluated in a combined analysis of three phase III trials in patients with metastatic bone disease receiving antiresorptive therapies.
Patients and methods
Patients with bone metastases secondary to solid tumors or myeloma were randomly assigned to receive either s.c. denosumab (120 mg) or i.v. zoledronic acid (4 mg) every 4 weeks. On-study oral examinations were conducted by investigators at baseline and every 6 months. Oral adverse events were adjudicated by an independent blinded committee of dental experts.
Results
Of 5723 patients enrolled, 89 (1.6%) patients were determined to have ONJ: 37 (1.3%) received zoledronic acid and 52 (1.8%) received denosumab (P = 0.13). Tooth extraction was reported for 61.8% of patients with ONJ. ONJ treatment was conservative in >95% of patients. As of October 2010, ONJ resolved in 36.0% of patients (29.7% for zoledronic acid and 40.4% for denosumab).
Conclusions
In this combined analysis of three prospective trials, ONJ was infrequent, management was mostly conservative, and healing occurred in over one-third of the patients. Educating physicians about oral health before and during bone-targeted therapy may help reduce ONJ incidence and improve outcomes.
Elsevier